Literature DB >> 35945299

Questionable value of [99mTc]-sestamibi scintigraphy in patients with pHPT and negative ultrasound.

Christina Lenschow1, Andreas Wennmann1, Anne Hendricks1, Christoph-Thomas Germer1, Martin Fassnacht2, Andreas Buck3, Rudolf A Werner3, Lars Plassmeier1, Nicolas Schlegel4.   

Abstract

PURPOSE: A successful focused surgical approach in primary hyperparathyroidism (pHPT) relies on accurate preoperative localization of the parathyroid adenoma (PA). Most often, ultrasound is followed by [99mTc]-sestamibi scintigraphy, but the value of this approach is disputed. Here, we evaluated the diagnostic approach in patients with surgically treated pHPT in our center with the aim to further refine preoperative diagnostic procedures.
METHODS: A single-center retrospective analysis of patients with pHPT from 01/2005 to 08/2021 was carried out followed by evaluation of the preoperative imaging modalities to localize PA. The localization of the PA had to be confirmed intraoperatively by the fresh frozen section and significant dropping of the intraoperative parathyroid hormone (PTH) levels.
RESULTS: From 658 patients diagnosed with pHPT, 30 patients were excluded from the analysis because of surgery for recurrent or persistent disease. Median age of patients was 58.0 (13-93) years and 71% were female. Neck ultrasound was carried out in 91.7% and localized a PA in 76.6%. In 23.4% (135/576) of the patients, preoperative neck ultrasound did not detect a PA. In this group, [99mTc]-sestamibi correctly identified PA in only 25.4% of patients. In contrast, in the same cohort, the use of [11C]-methionine or [11C]-choline PET resulted in the correct identification of PA in 79.4% of patients (OR 13.23; 95% CI 5.24-33.56).
CONCLUSION: [11C]-Methionine or [11C]-choline PET/CT are superior second-line imaging methods to select patients for a focused surgical approach when previous ultrasound failed to identify PA.
© 2022. The Author(s).

Entities:  

Keywords:  Focused surgical approach; Parathyroid adenoma; Primary hyperparathyroidism; [11C]-Choline PET/CT; [11C]-Methionine; [99mTc]-Sestamibi scan

Year:  2022        PMID: 35945299     DOI: 10.1007/s00423-022-02648-9

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   2.895


  5 in total

1.  Clinical impact of SPECT-CT in the diagnosis and surgical management of hyper-parathyroidism.

Authors:  Handan Tokmak; Mehmet Onur Demirkol; Faruk Alagöl; Serdar Tezelman; Tarik Terzioglu
Journal:  Int J Clin Exp Med       Date:  2014-04-15

2.  Mortality and Morbidity in Mild Primary Hyperparathyroidism: Results From a 10-Year Prospective Randomized Controlled Trial of Parathyroidectomy Versus Observation.

Authors:  Mikkel Pretorius; Karolina Lundstam; Ansgar Heck; Morten W Fagerland; Kristin Godang; Charlotte Mollerup; Stine L Fougner; Ylva Pernow; Turid Aas; Ola Hessman; Thord Rosén; Jörgen Nordenström; Svante Jansson; Mikael Hellström; Jens Bollerslev
Journal:  Ann Intern Med       Date:  2022-04-19       Impact factor: 51.598

3.  Can Met-PET/CT Predict Sporadic Multiglandular Hyperparathyroidism? Report of a Case and Review of the Literature.

Authors:  Andreas Hillenbrand; Johannes Lemke; Doris Henne-Bruns; Ambros J Beer; Vikas Prasad
Journal:  Case Rep Endocrinol       Date:  2019-05-15

4.  [18F]fluoro-ethylcholine-PET Plus 4D-CT (FEC-PET-CT): A Break-Through Tool to Localize the "Negative" Parathyroid Adenoma. One Year Follow Up Results Involving 170 Patients.

Authors:  Constantin Smaxwil; Philip Aschoff; Gerald Reischl; Mirjam Busch; Joachim Wagner; Julia Altmeier; Oswald Ploner; Andreas Zielke
Journal:  J Clin Med       Date:  2021-04-13       Impact factor: 4.241

5.  Selective venous sampling supports localization of adenoma in primary hyperparathyroidism.

Authors:  Masaya Ikuno; Takayuki Yamada; Yasumoto Shinjo; Tsuyoshi Morimoto; Reiko Kumano; Kunihiro Yagihashi; Takuyuki Katabami; Yasuo Nakajima
Journal:  Acta Radiol Open       Date:  2018-02-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.